Acute Coronary Syndrome Treatment Costs from the Perspective of the Supplementary Health System

Vanessa Teich¹, Tony Piha², Lucas Fahham¹, Haline Bianca Squissi¹, Everton de Matos Paloni³, Paulo Miranda², Denizar Vianna Araújo⁴
MedInsight¹, São Paulo, SP; AstraZeneca Brasil², Cotia, SP; Orizon³, São Paulo, SP; Departamento de Clínica Médica da Universidade do Estado do Rio de Janeiro⁴, Rio de Janeiro, RJ – Brazil

Abstract

Background: Acute coronary syndrome (ACS) is defined as a “group of clinical symptoms compatible with acute myocardial ischemia”, representing the leading cause of death worldwide, with a high clinical and financial impact. In this sense, the development of economic studies assessing the costs related to the treatment of ACS should be considered.

Objective: To evaluate costs and length of hospital stay between groups of patients treated for ACS undergoing angioplasty with or without stent implantation (stent+ / stent-), coronary artery bypass surgery (CABG) and treated only clinically (Clinical) from the perspective of the Brazilian Supplementary Health System (SHS).

Methods: A retrospective analysis of medical claims of beneficiaries of health plans was performed considering hospitalization costs and length of hospital stay for management of patients undergoing different types of treatment for ACS, between Jan/2010 and Jun/2012.

Results: The average costs per patient were R$ 18,261.77, R$ 30,611.07, R$ 37,454.94 and R$ 40,883.37 in the following groups: Clinical, stent-, stent+ and CABG, respectively. The average costs per day of hospitalization were R$ 1,987.03, R$ 4,024.72, R$ 6,033.40 and R$ 2,663.82, respectively. The average results for length of stay were 9.19 days, 7.61 days, 6.19 days and 15.20 days in these same groups. The differences were significant between all groups except Clinical and stent- and between stent + and CABG groups for cost analysis.

Conclusion: Hospitalization costs of SCA are high in the Brazilian SHS, being significantly higher when interventional procedures are required. (Arq Bras Cardiol. 2015; 105(4):339-344)

Keywords: Acute Coronary Syndrome / economy; Health Care Costs; Health Expenditures; Data Interpretation, Statistical; Prepaid Health Plans.

Introduction

Acute coronary syndrome (ACS) is defined by the American Heart Association as a “group of clinical symptoms compatible with acute myocardial ischemia”. Its clinical spectrum includes unstable angina and acute myocardial infarction (AMI) with or without ST-segment elevation.

According to Polanczyk and Ribeiro¹, prevalence data in Brazil estimate that 5% to 8% of adults older than 40 years old have ACS¹. The disease is the leading cause of mortality in Brazil² and developed countries³. It is estimated that for every 5 to 7 cases of myocardial infarction there is one death⁴. Thus, coronary heart disease is the leading cause of death worldwide, making it one of the diseases with the highest clinical and financial impact⁴.

Several types of interventions have been shown to be beneficial for the management of ACS, including the use of medications such as antiplatelet agents, beta-blockers, heparin, glycoprotein IIb/IIIa inhibitors and the use of procedures such as catheterization and thrombolytic therapy such as coronary angioplasty and revascularization⁶.

Currently in Brazil there are no studies comparing the costs of different types of treatment for ACS in SHS. Studies such as this are needed to make it possible to evaluate the economic impact a disease such as ACS has on society.

Thus, the objective of this article is to evaluate the costs and the length of hospital stay between groups of patients that were treated for ACS, submitted to angioplasty with or without stenting (stent + / stent-), revascularization (CABG) and treated only clinically (Clinical), from the perspective of the Brazilian Supplementary Health System (SHS).

Methods

A retrospective analysis was carried out of medical claims from beneficiaries of health care provided by private institutions in all Brazilian regions (excluding the states of Tocantins, Roraima and Mato Grosso do Sul), through a
The median costs among the four groups were compared using the Kruskal-Wallis method, which showed a p-value < 0.001, rejecting the hypothesis of equality between the costs. A post-hoc test was used to perform the pairwise comparison, as shown in Table 3.

The comparison analysis of the median costs of treatment, in the period between 1/2010 and 6/2012, indicated that the difference was not significant when comparing the Clinical group with stent- group and in the comparison between the stent+ group and CABG group. All other comparisons showed statistically significant differences.

The representativeness of the types of cost in the four analyzed groups is shown in Figure 1.

The chart analysis shows that the stent-, stent+ and CABG groups had higher cost with materials and procedures (representing > 50% of the total cost of each group), while in the Clinical group this cost is only 18%. The Clinical group showed that most of the costs are related to medications and fees (58%), which was expected, as the cost is basically restricted to the use of medications and consultations.

The results of the analysis of hospital stay of the four groups and the mean cost per day of hospitalization are shown in Table 4. Patients in the Clinical group showed a minimum hospital stay of two days and a maximum of 35 days. In the stent+ patients group, the hospital stay varied from one day to a maximum of 515 days. Patients in the stent- group had a maximum length of stay of 80 days, while in the CABG group patients showed a variation in hospital stay from four to 50 days.

To test the normality of the data related to the length of stay, exploratory analysis was performed through a QQ Plot graphic, and non-adherence to a normal distribution was confirmed by the Shapiro-Wilk test (p < 0.001). Therefore, it was decided to analyze the data by non-parametric methods. Thus, when comparing the mean length of hospital stay, the mean costs among the four groups were compared using the Kruskal-Wallis method, which showed a p-value < 0.001, rejecting the hypothesis of equality between lengths of hospitalization. A post-hoc test was used to perform the pairwise comparison, as shown in Table 5.

Regarding the median hospitalization time, only the comparison of the Clinical group versus the stent- group was not significant. All other comparisons showed significant results. These results can be confirmed graphically in Figure 2, where the confidence interval of the difference between mean lengths of hospitalization crosses the vertical axis of the graph only for the comparison between Clinical and stent- groups.

The analysis of total costs showed that the highest costs in the Clinical group were related to medications, followed by procedures, fees and medications. The results of the analysis of the mean costs per procedure, segmented by group, are shown in Table 2.
Table 1 – Total cost of hospital treatment by type of cost

| Type of cost         | Clinical   | stent-     | stent+     | CABG       |
|---------------------|------------|------------|------------|------------|
| Food                | R$ 8,735.28| R$ 62,470.20| R$ 205,822.95| R$ 39,885.35|
| Examination         | R$ 122,649.76| R$ 559,699.66| R$ 4,374,932.76| R$ 574,814.36|
| Medical Gases       | R$ 72,369.09| R$ 198,039.56| R$ 848,664.42| R$ 217,487.94|
| Hygiene/Cosmetics   | R$ 897.14  | R$ 1,125.15 | R$ 10,062.67 | R$ 1,823.80 |
| Fees                | R$ 82,786.31| R$ 131,965.21| R$ 1,425,054.16| R$ 276,275.32|
| Materials           | R$ 196,965.06| R$ 2,139,035.25| R$ 55,820,543.70| R$ 2,629,796.09|
| Medications         | R$ 357,560.41| R$ 961,490.33| R$ 4,955,775.35| R$ 971,924.45|
| Procedures          | R$ 16,969.35| R$ 1,101,482.66| R$ 13,435,554.79| R$ 2,219,036.26|
| Taxes               | R$ 311,558.95| R$ 1,210,965.32| R$ 8,724,484.12| R$ 1,654,395.39|
| Others              | R$ 0.00    | R$ 841.11   | R$ 3,696.23  | R$ 104.40   |
| Total               | R$ 1,150,491.35| R$ 6,367,102.45| R$ 89,704,591.15| R$ 8,585,507.36|

CABG: Coronary artery bypass surgery.

Table 2 – Mean cost per procedure by type of cost

| Type of cost         | Clinical   | stent-     | stent+     | CABG       |
|---------------------|------------|------------|------------|------------|
| Food                | R$ 138.66  | R$ 300.34  | R$ 85.69   | R$ 188.14  |
| Examination         | R$ 1,046.82| R$ 2,690.86| R$ 1,821.37| R$ 2,711.39|
| Medical Gases       | R$ 1,148.72| R$ 952.11  | R$ 353.32  | R$ 1,025.89|
| Hygiene/Cosmetics   | R$ 14.24   | R$ 5.41    | R$ 4.19    | R$ 8.60    |
| Fees                | R$ 996.61  | R$ 634.39  | R$ 593.28  | R$ 1,303.19|
| Materials           | R$ 3,126.43| R$ 10,283.82| R$ 23,239.19| R$ 12,404.70|
| Medications         | R$ 5,675.56| R$ 4,622.55| R$ 2,021.56| R$ 4,584.55|
| Procedures          | R$ 269.35  | R$ 5,295.95| R$ 5,593.49| R$ 10,467.15|
| Taxes               | R$ 4,945.38| R$ 5,821.95| R$ 3,632.17| R$ 7,803.58|
| Others              | R$ 0.00    | R$ 4.05    | R$ 1.53    | R$ 0.49    |
| Total               | R$ 18,261.77| R$ 30,611.07| R$ 37,345.79| R$ 40,497.68|

CABG: Coronary artery bypass surgery.

Table 3 – Cost comparison between groups

|          | Clinical | stent+ | stent- | CABG |
|----------|----------|--------|--------|------|
|          |          | S      | NS     | S    |
| Clinical |          |        |        |      |
| stent+   |          |        |        |      |
| stent-   |          | S      | NS     | S    |
| CABG     |          |        |        |      |

S: Significant; NS: Non-significant; CABG: Coronary artery bypass surgery.
An important finding of this analysis is related to the fact that the mean cost results did not show a statistically significant difference between the clinically treated group and the group submitted to angioplasty without stenting, as well as between the group treated by CABG and the group submitted to angioplasty with stenting. This finding suggests that patients treated with angioplasty without stenting and those submitted only to clinical treatment have similar treatment costs, which can be explained by the lower complexity of angioplasty, often performed on an outpatient basis and with shorter hospital length of stay.

Patients undergoing CABG and those submitted to angioplasty with stent implantation showed similar costs between them and higher costs when compared to less complex procedures (angioplasty without stent and clinical treatment), representing significant expenditures for the treatment of patients with ACS.
A retrospective study carried out in France, involving 154 patients with ACS and submitted to angioplasty with stent implantation in 2005, concluded that the costs involved in performing this procedure have a financial impact for hospitals.8

Another study carried out in Brazil measured direct and indirect costs related to the treatment of ACS, from the perspectives of the Unified Health System (SUS) and Supplementary Health System. The study considered the historical series of hospitalizations in SUS between 1999 and 2010 and the expected number of hospitalizations for 2011 projected by a linear extrapolation of the historical series and concluded that the estimated direct cost associated with ACS in 2011, from the SUS perspective, is approximately 0.77% of the total SUS budget, and from the SHS perspective, this estimate would come to R$ 515,138,617.9

Studies like this demonstrate the importance of following these patients, the pharmacological treatment and lifestyle changes that can contribute to preserving the health of patients and prevention of complications, in order to prevent patients from undergoing complex treatments that may excessively burden the health care system.

A limitation of the present study is the lack of a reliable national registry of cases of cardiovascular diseases and hence, the scarcity of supplementary medical data and other health care providers, as this study used data from health insurance companies linked to the Orizon® company.

Conclusions
In the present study it was observed that the clinical treatment and angioplasty without stenting procedure, associated with the use of antiplatelet agents, are less onerous for the SHS compared to major procedures such as angioplasty with stenting and CABG, as, due to the high degree of complexity, these procedures had higher associated costs and therefore should be considered as relevant costs to the health system.

Author contributions
Conception and design of the research: Teich V, Piha T, Fahham L, Squiassi HB, Paloni EM, Araújo DV, Miranda P. Acquisition of data: Piha T, Paloni EM. Analysis and interpretation of the data: Teich V, Piha T, Fahham L, Squiassi HB, Araújo DV, Miranda P. Statistical analysis: Fahham L. Obtaining financing: Teich V, Piha T, Miranda P. Writing of the manuscript: Squiassi HB. Critical revision of the manuscript for intellectual content: Teich V, Piha T, Fahham L, Paloni EM, Araújo DV, Miranda P.
Potential Conflict of Interest

Drs. Tony Piha and Paulo Miranda are employees of AstraZeneca Brazil. Vanessa Teich, Lucas Fahham, Haline Bianca Squiassi are employees of Medinsight, company that received funding from AstraZeneca to perform the analysis and preparation of the article.

Sources of Funding

This study was funded by AstraZeneca do Brasil.

Study Association

This study is not associated with any thesis or dissertation work.

References

1. Polanczyk CA, Ribeiro JP. Coronary artery disease in Brazil: contemporary management and future perspectives. Heart. 2009;95(11):870-6.
2. Souza e Silva NA. Saúde cardiovascular na era tecnológica. Arq Bras Cardiol. 2004;83(6):453-5.
3. Grech ED, Ramsdale DR. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. BMJ. 2003;326(7401):1259-61.
4. Ministério da Saúde. Protocolo Clínico Síndromes Coronarianas Agudas. Brasília; 2011. [Acesso em 2013 January 21]. Disponível em: http://portal.saude.gov.br/portal/arquivos/pdf/protocolo_clinico_sindromes_coronarianas_agudas.pdf
5. Polanczyk CA, Prado K, Borges MS, Ribeiro JP. Acute myocardial infarction in the thrombolytic era: high mortality in elderly patients. Rev Assoc Med Bras. 1993;39(2):65-72.
6. Pesaro AE, Campos PC, Corrêa TD, Knobel E. Síndromes coronarianas agudas: tratamento e estratificação de risco. Rev Bras Ter Intensiva. 2008;20(2):197-204.
7. R Core Team (2014). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
8. Nidegger D, Metz D, Vacter C, Tassan-Mangina S, Deschildre A, Gawron M, et al. Financial impact of coronary stenting in emergency for acute coronary syndromes. Arch Cardiovasc Dis. 2009;102(5):409-18.
9. Teich V, Araujo DV. Estimativa de custo da síndrome coronariana aguda no Brasil. Rev Bras Cardiol. 2011;24(2):85-94.